Monday, January 04, 2021 6:00:43 PM
I think we all recognize that.
Any revenue being generated is better then no revenue.
Because that will cut down on dilution.
In terms of this Deal - ultimately the Devil is in the Details.
If there was upfront cash I think they would have said that.
What I noticed is that Arch appears to have entered into an agreement for all products. Basic AC5 plus all future products.
Internal is where the money is....
Did they cut the deal to gain a little cash and for PR reasons - only to have given away rights to internal for a smidgeon of what it may be worth if it finally gets approved..?
Who knows.
We will see what they have to say about this in the coming weeks and months.
Hopefully this brings in revenue so they can minimize dilution.
Without that..............................
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM